(Q28189075)

English

Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects

scientific article (publication date: September 2001)

In more languages

Statements

scholarly article

0 references

Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects (English)

0 references

pharmacodynamics

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

U Klinkhardt

1

0 references

J Graff

2

0 references

D Westrup

3

0 references

C M Kirchmaier

4

0 references

H U Esslinger

5

0 references

H K Breddin

6

0 references

S Harder

7

0 references

language of work or name

0 references

publication date

September 2001

0 references

British Journal of Clinical Pharmacology

0 references

52

0 references

3

0 references

297-305

0 references

Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

20 March 2017

Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

29 September 2017

Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

29 September 2017

Management strategies in unstable coronary artery disease--current problems and future directions. The UCAD Council

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

29 September 2017

Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

29 September 2017

Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, E

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

29 September 2017

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

29 September 2017

Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

29 September 2017

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

2 June 2018

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

2 June 2018

Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

2 June 2018

Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

2 June 2018

Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

2 June 2018

Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

2 June 2018

Heparin and low molecular weight heparin but not hirudin stimulate platelet aggregation in whole blood from acetylsalicylic acid treated healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

2 June 2018

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014552

20 June 2018

Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01446.X

21 January 2018

Platelet activation and coronary stent implantation. Effect of antithrombotic therapy.

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01446.X

21 January 2018

Platelet GPIIb-IIIa blockers

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01446.X

21 January 2018

Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pursuing progress in acute coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

GMP-140 mediates adhesion of stimulated platelets to neutrophils

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heparin potentiation of collagen-induced platelet aggregation is related to the GPIIb/GPIIIa receptor and not to the GPIb receptor, as tested by whole blood aggregometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined thrombolytic and platelet glycoprotein IIb/IIIa inhibitor therapy for acute myocardial infarction: will pharmacological therapy ever equal primary angioplasty?

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with tirofiban and enoxaparin in acute coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/11560562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1046/J.0306-5251.2001.01446.X

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28189075&oldid=1585783889"